Cognizant And Gilead Deepen AI-Powered Partnership For Innovation

Cognizant announced expanded partnership terms with Gilead Sciences, which enhances the vision of extracting maximum business value through disease prevention and treatment innovation. The enlarged agreement creates opportunities for Gilead to achieve better cost performance and productivity advancement as it brings new value from its present partnership. The work implements a framework with machine learning and generative AI solutions to solve customer service challenges, employee engagement needs, and business value enhancement. The technological expertise from Cognizant will help Gilead become more efficient with its operations. The deployment of advanced solutions throughout Cognizant's value chain will enable Gilead to obtain significant benefits by using an improved financial optimization approach.

Joydeep Ganguly, SVP & Head – Corporate Operations and Interim CIO at Gilead, commented, "Cognizant continues to provide critical expertise as we advance our technology journey. The expansion of this partnership is pivotal in accelerating our capabilities roadmap while driving a new level of cost leadership across our technology programs. This collaboration aims to bring innovative changes to Gilead's business, exploring new possibilities and enhancing our operations in novel ways."

"We're proud of our longstanding relationship with Gilead, a leader in leveraging advanced technologies, and are excited about expanding our partnership in a new dimension with the company to deliver transformative treatments globally. Our teams will work together to transform user engagement and boost productivity and cost savings for Gilead to focus on the critical work they do around preventing and treating life-threatening illnesses," said Surya Gummadi, EVP and President Cognizant Americas.

For over a decade, Cognizant has supported Gilead’s global IT systems, helping drive its digital transformation. Now, with this expanded agreement, Cognizant will introduce its Neuro AI platform to make Gilead’s IT and business processes even smarter. This should lead to significant cost savings, which Gilead can reinvest in developing new treatments for diseases like cancer and HIV. Additionally, Cognizant plans to enhance Gilead’s IT services with AI-powered tools that improve efficiency and the overall user experience. This collaboration helps Gilead focus on discovering and delivering critical medicines. 

Mohammad Haque, SVP, Global Large Deals Lead and Business Unit Head, Life Sciences, Cognizant, said in a statement, "This agreement allows us to provide end-to-end Cognizant capabilities through our life sciences domain expertise to provide value acceleration to Gilead. Utilizing Cognizant's premier managed services frameworks and tools, we intend to enhance operational efficiencies with leading-edge automation."